Displaying 37 - 48 of 60
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unfolding the metabolic dysfunction of MASH: exploring the pathophysiology and outcomes - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Displaying 37 - 48 of 60